Trial Profile
A Phase II Study Evaluating the Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk Diffuse Large B-cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Nov 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 19 Jan 2022 Planned End Date changed from 1 Apr 2025 to 1 Jan 2027.
- 19 Jan 2022 Planned primary completion date changed from 1 Apr 2022 to 18 Jan 2024.
- 19 Jan 2022 Status changed from recruiting to active, no longer recruiting.